Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
International Journal of Laboratory Medicine ; (12): 2045-2046, 2015.
Artículo en Chino | WPRIM | ID: wpr-465150

RESUMEN

Objective To analyse the suffer′excrescent circumstance in chromosome who are primary amenorrhea or secondary amenorrhea and inquiry its clinical meaning .Methods Take out patients′peypheyal vein blood to cultuve ,the chromosome was pre‐pared ,G band was analysed .Results primary amenorrhea or secondary amenorrhea suffer totally 225 ,there were 63 with chromo‐som abnormal karyotyptes which occupies 28% ;Among 148 the patiens of primary amenorrhea ,chromosom abnormal karyotyptes were 55 examples which occupies 37 .16% ,secondary amenorrhea is 77 examples ,chromosom abnormal karyotyptes were 8 exam‐ples which occupies 10 .39% .Conclusion Chromosome abnormals are the main cause of primary amenorrhea and secondary amen‐orrhea .in patients with chromosom analyse ,to kncw the cause of amenorrhea ,early symptomatic treatment is important .

2.
Chinese Journal of Clinical Pharmacology and Therapeutics ; (12)2000.
Artículo en Chino | WPRIM | ID: wpr-679197

RESUMEN

AIM: To evaluate the clinical efficacy of combination of active immunotherapy and allylestrenol in treatment of patients with unexplained recurrent spontaneous abortion (URSA) and to investigate a best therapeutic method in treatment of patients with URSA. METHODS: 435 patients with primary URSA were randomly assigned to three groups: 185 in combination medication group which was treated with active immunotherapy and allylestrenol, 152 in active immunotherapy group which was only treated with active immunotherapy, 98 in allylestrenol group which was only treated with allylestrenol. 96 secondary URSA in secondary URSA group were treated with active immunotherapy and allylestrenol. RESULTS: The successful pregnant rates of combination medication group, active immunotherapy group, allylestrenol group and secondary group were 92.05 %, 71.43 %, 31.51 % and 86.76 %, respectively. The successful pregnant rate in combination group were higher than that in the active immunotherapy group and the allylestrenol group (P 0.05 ). CONCLUSION: Combination of active immunotherapy and allylestrenol is better than other therapy method in treatment of patients with URSA, which is worth further widespread application in clinical practice.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA